ヨーロッパの膀胱疾患市場 – 業界動向と2029年までの予測

ヨーロッパの膀胱疾患市場の分析と洞察 

膀胱障害は、人間の日常生活に影響を及ぼす可能性のある障害のグループです。最も一般的な膀胱障害には、膀胱炎（膀胱が感染して炎症を起こす）、尿失禁（膀胱をコントロールできなくなる）、間質性膀胱炎（膀胱の痛みと頻尿、切迫した排尿）、過活動膀胱（膀胱が尿を絞り出す状態）などがあります。膀胱障害は生活の質に影響を及ぼし、その他の健康上の問題を引き起こす可能性があります。神経系や生活習慣の要因を含む健康の変化や問題は、男性と女性の UI の原因または一因となる可能性があります。

最も一般的な膀胱障害は、過活動膀胱と UI です。これらの問題は神経系に関連しています。神経は脳から膀胱に筋肉の収縮または弛緩を指示するメッセージを伝えます。

ヨーロッパの膀胱障害市場は、2022年から2029年の予測期間に成長すると予想されています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に10.7%のCAGRで成長し、2021年の23億3,269万米ドルから2029年には52億2,600万米ドルに達すると分析しています。

ヨーロッパの膀胱疾患市場の市場定義

Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, urinary incontinence - loss of bladder control, overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.

Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.

Anticholinergic medications are the first-line of pharmacotherapy in overactive bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.

Europe Bladder Disorders Market Dynamics

Drivers

• STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.

• GROWING GERIATRIC POPULATION

Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

• RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

• COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

• SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.

• RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems coupled with increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This Bladder Disorders Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe Bladder Disorders Market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Europe Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

• In February, AbbVie announced the U.S. FDA approval for the BOTOX® for treating detrusor (bladder muscle) over activity associated with a neurologic condition in pediatric patients 5 years of age. "BOTOX® is the first neurotoxin authorized to treat neurogenic detrusor over activity in children whose condition cannot be successfully treated by anticholinergic therapy." This approval will increase the revenue of the company

Europe Bladder Disorders Market Scope

Europe bladder disorders market is segmented into type, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

• Cystitis
• Urinary Incontinence
• Overactive Bladder
• Interstitial Cystitis
• Bladder Cancer

On the basis of type, the Europe bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, and bladder cancer

Treatment type

• Surgery
• Medications
• Others

On the basis of product, the Europe bladder disorders market is segmented into surgery, medication, and others

End user

• Hospital
• Clinics
• Ambulatory Surgery centers
• Others

On the basis of end users, the Europe bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others

Distribution Channel

• Direct
• Retail

On the basis of distribution channel, the Europe bladder disorders market is segmented into direct and retail

Europe Bladder Disorders Market Regional Analysis/Insights  

Europe bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.

Countries covered in this market are Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.

Germany dominates the Europe bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europe brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Bladder Disorders Market Share Analysis

ヨーロッパの膀胱障害市場の競争状況は、競合他社に関する詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、アジア太平洋地域でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。上記のデータ ポイントは、ヨーロッパの膀胱障害市場への会社の重点にのみ関連しています。

ヨーロッパの膀胱疾患市場で活動している主要企業には、メドトロニック、ラボリー、ボストン・サイエンティフィック・コーポレーション、ファイザー社、アステラス製薬、杏林製薬株式会社（杏林製薬ホールディングス株式会社の子会社）、ブリストル・マイヤーズ スクイブ社、ジョンソン・エンド・ジョンソン・サービシズ社、アクソニクス社、メルク社、ビアトリス社、ブルー・ウィンド・メディカル、ゲイロード・ケミカル社、コロプラスト社、アッヴィ社、サン・ファーマシューティカル・インダストリーズ社、ザイダス・グループ、ウロバント・サイエンシズなどがある。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、ヨーロッパと地域、ベンダー シェア分析が含まれます。さらに質問がある場合は、アナリストへの電話をリクエストしてください。

SKU-69071